NANO THERAPIES, MEGA RESULTS
Saving lives with targeted
Radiotherapeutics
to treat cancer patients
We are an innovative radiopharmaceutical company developing tumor-specific precision therapeutics. Our mission is to provide another chance at a cancer-free life for oncology patients.
About Us
-
Our Science
Our cutting-edge research is focused on the development of meticulously designed nanocarriers, tailored for precise and targeted delivery of therapeutics, backed by a robust global intellectual property portfolio.
-
Our Pipeline
We boast a robust and dynamic product pipeline, encompassing a wide range of innovative concepts progressing seamlessly from early-stage ideation to advanced stages of clinical trial readiness.
-
Our Team
We are a synergistic alliance of visionary inventors, accomplished entrepreneurs, eminent research scientists, and astute business experts united by shared determination for success and making a positive impact on peoples’ lives.
-
Our Publications and Awards
Our continuous innovation and steadfast commitment to rigorous scientific research are reflected in our extensive array of publications and prestigious awards.
Our Science
Our groundbreaking innovation, XLNT-1, radionuclide 166Ho-containing nanoparticles, meticulously designed to specifically target and combat tumors and metastasis in the peritoneal cavity.
Tumor-specific delivery
With most IV administered nanotechnologies, only ~ 0.7% of administered dose reaches tumors.
XLNT-1 delivered up to 82% dose/g in tumor tissues.
Tumor tissue penetration
Conventionally delivered dose can’t reach deep into tumors; incomplete tumor regression.
Radiation emitted from XLNT-1 promotes deep tumor penetration of nanoparticles.
Simple and Scalable manufacturing
Scaling the manufacturing of radioactive nanoparticles and liposomes is challenging.
The manufacture of XLNT-1 is readily scalable; radioactive XLNT-1 is prepared by a simple neutron-activation process that is conducted just prior to administration to the patient.
Improved treatment outcome of difficult-to-treat cancers
Current products offer little significant benefit in treating metastasis, resistance & recurrence.
Superior survival has been demonstrated with XLNT-1 targeting metastasis and peritoneal carcinoma.
XLNT-1 demonstrated a favorable safety profile in preliminary GLP toxicity studies.
XLNT-1 enables clinical SPECT or MR imaging for precise dose determination.
Our Pipeline
Series radiopharmaceuticals for multiple cancers with resistance and metastasis
Our Team
-
Xiuling Lu, PhD
CEO, Co-Founder
Fellow of American Association of Pharmaceutical Scientists (AAPS).
Over 16 years experience in drug formulation development, particularly advancing nanotechnologies for cancer therapy.
She is a distinguished luminary in the realm of nanoparticle-based therapeutics and their corresponding product advancement.
Key technology inventor with multiple patents
Professor at the University of Connecticut. She has served of Chair of the Faculty at the National Institute for Pharmaceutical Technology and Education, and presently holds the mantle of Associate Director at the Center for Pharmaceutical Processing Research, concurrently serving as a leader in the AAPS Nanotechnology Community.
-
Michael Jay, PhD
CSO, Co-Founder
Over 40 years experience in drug development, imaging agents, and radiopharmaceuticals
Former director of an FDA-registered cGMP facility
Founded five companies; one obtained IND for clinical trials
Professor emeritus at the University of North Carolina at Chapel Hill
-
Ruobing Xia, MBA/MIA
CCO, Co-Founder
Over 20 years experience in big pharma, managed budgets exceeding $100 million
Led successful product launches resulting in billion-dollar growth
Founder and board member of multiple startups
Responsible for global strategy, business development, sales, marketing, and commercial operations.
-
David Worthen, PhD JD
Head of R&D
Served on URI faculty in pharmaceutical science, chemical engineering, and neuroscience
Senior scientist, project manager, group leader, and principal investigator at BMS, Alcinous Pharmaceuticals, and Yaupon Therapeutics
-
Jeffrey C. Miller, MBA
Business Advisor
Partner at KASTx Ventures, Co-founder of TSP Therapeutics
Over 25 years in the bio/pharmaceutical industry across small to large companies
Worked in over 15 countries, leading both mature and start-up businesses across numerous therapeutic areas spanning rare diseases, oncology, primary and specialty care
-
Al Paz, MBA
Business Advisor
Founder, President, and CEO of TSP Therapeutics, Inc.
Nearly four decades experience as a leader in the bio/pharmaceutical industry,
Working on nearly all sizes of business across 10 therapeutic areas, including four in the Oncology space.
Conceptualizing and executing market shaping innovations
-
Andrew Salner, MD
Clinical Advisor
Medical Director, Hartford HealthCare Cancer Institute at Hartford Hospital
More than 40 years clinical experience in Radiation Oncology
American Cancer Society George Sheehan Humanitarian Award
Lane Adams Quality of Life Award
-
Ron Pion, MD
Clinical Advisor
Clinical Professor at the UCLA School of Medicine and a Fellow of the American College of Obstetricians and Gynecologists
A pioneer in telemedicine and tele-health with more than 30 years of experience.
Our Publications and Awards
Rigorous science with demonstrated consistent outcome:
Di Pasqua AJ, Huckle JE, Kim JK, Chung Y, Wang AZ, Jay M and Lu X. Preparation of neutron activatable holmium nanoparticles for the treatment of ovarian cancer metastases. Small. 2012, 8 (7): 997-1000
Di Pasqua AJ, Miller ML, Lu X, Peng L, Jay M., Tumor accumulation of neutron activatable holmium-containing mesoporous silica nanoparticles in an orthotopic non-small cell lung cancer mouse model, Inorganica Chimica Acta. 2012, 393: 334–336
Di Pasqua AJ, Yuan H, Chung Y, Kim JK, Huckle JE, Li C, Sadgrove M, Tran TH, Jay M, Lu X. Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer. Journal of Nuclear Medicine. 2013, 54:111-116
Fu Q, Hargrove D, Lu X. Improving Paclitaxel Pharmacokinetics by Using Tumor-Specific Mesoporous Silica nanoparticles with Intraperitoneal Delivery. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016, 12: 1951–1959.
Kim J, Narayan R, Lu X, Jay M. Neutron-Activatable Needles for Radionuclide Therapy of Solid Tumors. Journal of Biomedical Materials Research Part A. 2017,105(12):3273-3280
Kim J, Luo ZX, Wu Y, Lu X, Jay M. In-situ formation of holmium oxide in pores of Mesoporous Carbon Nanoparticles as substrates for neutron-activatable radiotherapeutics . Carbon. 2017, 117: 92–99.
Kashfi-Sadabad R, Gonzalez-Fajardo L, Hargrove D, Ahmadi B, Munteanu D, Shahbazmohamadi S, Jay M and Lu X. Engineering multi-functional gold decorated dendritic mesoporous silica/tantalum oxide nanoparticles for intraperitoneal tumor-specific delivery. Particle and Particle Characterization. 2019, 36 (4):1-10
D Hargrove, B Liang, R Kashfi-Sadabadi, G N. Joshi, L Gonzalez-Fajardo, S Glass, M Jay, A Salner, X Lu. Tumor-mesoporous silica nanoparticle Interactions Following Intrapritoneal Delivery for Targeting Peritoneal Metastasis. Journal of Controlled Release. 2020 Dec 10;328:846-858
Awards
Careers
Join Our Team and Make a Difference
We are continuously seeking exceptional talent driven by a passion to make a difference in the lives of our patients and contribute to the success of our business. If you are ready to make a meaningful impact, we invite you to explore the exciting opportunities we have available in following areas:
Clinical Research and Development
Regulatory Affairs
Formulation and PKPD Researchers
Business Development
Please don’t forget to check back regularly, as we frequently update our openings and look forward to welcoming new talent.